Alpha Cognition Inc (ACOG)

$5.76 -0.03 (-0.52%)
Market Cap 125.02M
Revenue (ttm) 0.00
Net Income (ttm) -14.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,038
Avg Vol 68,508
Day's Range N/A - N/A
Shares Out 21.74M
Stochastic %K 23%
Beta 2.55
Analysts Sell
Price Target $18.00

Company Profile

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatit...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 564 9244
Address:
750 West Pender Street, Suite 1200, Vancouver, Canada
Bioinvester001
Bioinvester001 Mar. 16 at 2:38 PM
$ACOG Earnings could show a big increase in payer accounts. Could be this stock is finally ready to move up.
0 · Reply
jumptime
jumptime Mar. 12 at 6:03 PM
$ACOG When....?
0 · Reply
JackCampbell
JackCampbell Mar. 11 at 9:55 AM
$ACOG FYI: Institutional Shares (Long) 9,909,100/ +45.58% (ex 13D/G) - change of +4.33MM shares +77.53% MRQ Institutional Value (Long) $ 64,397 USD ($1000)
0 · Reply
FlowerInTheCellar
FlowerInTheCellar Mar. 10 at 7:50 PM
$ACOG https://www.businesswire.com/news/home/20260310594648/en/Alpha-Cognition-to-Present-New-Clinical-on-ZUNVEYL-Benzgalantamine-at-Multiple-Upcoming-Alzheimers-Association-International-Conferences
0 · Reply
DARKP00L
DARKP00L Mar. 10 at 1:06 PM
$ACOG 08:32 on Mar. 10 2026 Alpha Cognition To Present New Clinical Data On ZUNVEYL Alzheimer's Treatment At AAGP From April 16 #tradeideas
0 · Reply
jumptime
jumptime Mar. 5 at 10:28 PM
$ACOG One of these days...
0 · Reply
ForestFoxes
ForestFoxes Feb. 26 at 8:29 AM
$ACOG https://www.reddit.com/r/AlphaCognition/s/06BlDzrQD8
1 · Reply
JackCampbell
JackCampbell Feb. 26 at 7:12 AM
$ACOG someone posted this interview on reddit. Eden Rahim is a Portfolio Manager at Next Edge Capital and an absolute expert in the biotech field with 30 yrs experience. He recommends 2 stocks which could grow 100% per year for the next five yrs. An incredible insight of a professional regarding ACOGs drug and potential: https://www.youtube.com/watch?v=IGV_VTDgvNA
0 · Reply
FlowerInTheCellar
FlowerInTheCellar Feb. 25 at 6:20 PM
$ACOG https://www.businesswire.com/news/home/20260225883160/en/Alpha-Cognition-Announces-First-Patient-Enrolled-in-BEACON-Real-World-Effectiveness-Study
0 · Reply
StockNews_Live
StockNews_Live Feb. 25 at 1:32 PM
$ACOG Alpha Cognition Inc. announced the enrollment of the first patient in BEACON, a Phase 4 real-world effectiveness study, to assess the impact of ZUNVEYL in the Long-Term Care (LTC) setting. The study a…
0 · Reply
Latest News on ACOG
Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

Mar 13, 2026, 1:46 PM EDT - 4 days ago

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences

Mar 10, 2026, 8:30 AM EDT - 7 days ago

Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

Feb 25, 2026, 8:30 AM EST - 20 days ago

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

Feb 18, 2026, 8:30 AM EST - 27 days ago

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution

Jan 7, 2026, 4:30 PM EST - 2 months ago

Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution

Alpha Cognition Inc. (ACOG) Discusses Commercial Adoption Metrics and Market Opportunity in Long-Term Care Transcript

Dec 2, 2025, 6:53 PM EST - 3 months ago

Alpha Cognition Inc. (ACOG) Discusses Commercial Adoption Metrics and Market Opportunity in Long-Term Care Transcript

Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners

Dec 1, 2025, 5:51 PM EST - 3 months ago

Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025

Nov 14, 2025, 9:46 AM EST - 4 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025

Alpha Cognition Inc. (ACOG) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:11 PM EST - 4 months ago

Alpha Cognition Inc. (ACOG) Q3 2025 Earnings Call Transcript

Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 13, 2025, 4:00 PM EST - 4 months ago

Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update

Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025

Oct 30, 2025, 8:30 AM EDT - 4 months ago

Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025

Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings

Oct 14, 2025, 4:30 PM EDT - 5 months ago

Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings

Alpha Cognition to Present Clinical Data at ASCP Annual Meeting

Oct 6, 2025, 8:30 AM EDT - 5 months ago

Alpha Cognition to Present Clinical Data at ASCP Annual Meeting

Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares

Sep 30, 2025, 11:14 PM EDT - 5 months ago

Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

Sep 30, 2025, 4:58 PM EDT - 6 months ago

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences

Aug 28, 2025, 1:00 PM EDT - 7 months ago

Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025

Aug 15, 2025, 5:10 PM EDT - 7 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025

Alpha Cognition Inc. (ACOG) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:54 PM EDT - 7 months ago

Alpha Cognition Inc. (ACOG) Q2 2025 Earnings Call Transcript

Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 14, 2025, 8:30 AM EDT - 7 months ago

Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update

Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview

Aug 4, 2025, 8:30 AM EDT - 8 months ago

Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview

Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer's Disease

Jul 29, 2025, 8:30 AM EDT - 8 months ago

Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer's Disease

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference

Jul 8, 2025, 8:30 AM EDT - 9 months ago

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference

Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Jul 1, 2025, 5:05 PM EDT - 9 months ago

Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity

May 19, 2025, 4:35 PM EDT - 10 months ago

Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025

May 19, 2025, 10:25 AM EDT - 10 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025

Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript

May 15, 2025, 9:51 PM EDT - 10 months ago

Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

May 15, 2025, 8:30 AM EDT - 10 months ago

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

May 1, 2025, 8:30 AM EDT - 11 months ago

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 30, 2025, 7:30 AM EDT - 11 months ago

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference

Apr 28, 2025, 8:30 AM EDT - 11 months ago

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Apr 10, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Apr 1, 2025, 4:27 PM EDT - 1 year ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 9:50 PM EDT - 1 year ago

Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease

Feb 12, 2025, 8:30 AM EST - 1 year ago

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Jan 30, 2025, 11:05 AM EST - 1 year ago

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Jan 14, 2025, 8:30 AM EST - 1 year ago

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China

Jan 8, 2025, 8:30 AM EST - 1 year ago

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call

Jan 6, 2025, 8:30 AM EST - 1 year ago

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call

Alpha Cognition Announces Partial Exercise of Over-allotment Option

Dec 16, 2024, 2:56 PM EST - 1 year ago

Alpha Cognition Announces Partial Exercise of Over-allotment Option

CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)

Dec 16, 2024, 11:51 AM EST - 1 year ago

CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)

Alpha Cognition Announces Voluntary Delisting from CSE

Dec 12, 2024, 6:41 PM EST - 1 year ago

Alpha Cognition Announces Voluntary Delisting from CSE

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Dec 11, 2024, 8:30 AM EST - 1 year ago

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Nov 15, 2024, 5:00 PM EST - 1 year ago

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

Nov 12, 2024, 9:22 AM EST - 1 year ago

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

Bioinvester001
Bioinvester001 Mar. 16 at 2:38 PM
$ACOG Earnings could show a big increase in payer accounts. Could be this stock is finally ready to move up.
0 · Reply
jumptime
jumptime Mar. 12 at 6:03 PM
$ACOG When....?
0 · Reply
JackCampbell
JackCampbell Mar. 11 at 9:55 AM
$ACOG FYI: Institutional Shares (Long) 9,909,100/ +45.58% (ex 13D/G) - change of +4.33MM shares +77.53% MRQ Institutional Value (Long) $ 64,397 USD ($1000)
0 · Reply
FlowerInTheCellar
FlowerInTheCellar Mar. 10 at 7:50 PM
$ACOG https://www.businesswire.com/news/home/20260310594648/en/Alpha-Cognition-to-Present-New-Clinical-on-ZUNVEYL-Benzgalantamine-at-Multiple-Upcoming-Alzheimers-Association-International-Conferences
0 · Reply
DARKP00L
DARKP00L Mar. 10 at 1:06 PM
$ACOG 08:32 on Mar. 10 2026 Alpha Cognition To Present New Clinical Data On ZUNVEYL Alzheimer's Treatment At AAGP From April 16 #tradeideas
0 · Reply
jumptime
jumptime Mar. 5 at 10:28 PM
$ACOG One of these days...
0 · Reply
ForestFoxes
ForestFoxes Feb. 26 at 8:29 AM
$ACOG https://www.reddit.com/r/AlphaCognition/s/06BlDzrQD8
1 · Reply
JackCampbell
JackCampbell Feb. 26 at 7:12 AM
$ACOG someone posted this interview on reddit. Eden Rahim is a Portfolio Manager at Next Edge Capital and an absolute expert in the biotech field with 30 yrs experience. He recommends 2 stocks which could grow 100% per year for the next five yrs. An incredible insight of a professional regarding ACOGs drug and potential: https://www.youtube.com/watch?v=IGV_VTDgvNA
0 · Reply
FlowerInTheCellar
FlowerInTheCellar Feb. 25 at 6:20 PM
$ACOG https://www.businesswire.com/news/home/20260225883160/en/Alpha-Cognition-Announces-First-Patient-Enrolled-in-BEACON-Real-World-Effectiveness-Study
0 · Reply
StockNews_Live
StockNews_Live Feb. 25 at 1:32 PM
$ACOG Alpha Cognition Inc. announced the enrollment of the first patient in BEACON, a Phase 4 real-world effectiveness study, to assess the impact of ZUNVEYL in the Long-Term Care (LTC) setting. The study a…
0 · Reply
FlowerInTheCellar
FlowerInTheCellar Feb. 24 at 8:08 PM
$ACOG https://www.businesswire.com/news/home/20260218956050/en/Alpha-Cognition-Announces-Issuance-of-Additional-U.S.-Patent-Covering-ZUNVEYL-Dosing-Regimens
0 · Reply
JackCampbell
JackCampbell Feb. 24 at 2:07 PM
$ACOG futher institutional investors are increasing their holdings i.e.: 2026-02-17 13F Cable Car Capital LLC latest: 1,060,212 (+22%) 2026-02-17 13F Sphera Funds Management Ltd. latest: 567,616 (+67.56%)
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 10:14 PM
$ACOG Current Stock Price: $5.85
0 · Reply
JackCampbell
JackCampbell Feb. 19 at 9:51 PM
$ACOG institutional investors are increasing their holdings i.e.: 2026-02-13 13G/A AWM Investment Company, Inc. previous shrs: 1,043,478 latest: 2,172,036 (+108.15%) ownership: 9.90% (+52.31%) 2026-02-06 13G Opaleye Management Inc. previous shrs: 1,875,142 latest: 2,070,784 (+10.43%) ownership: 9.52% (+6.13%)
0 · Reply
theflynews
theflynews Feb. 13 at 4:38 PM
Biotech Alert: Searches spiking for these stocks today - $ACOG - https://legacy.thefly.com/permalinks/entry.php/id4293085
0 · Reply
char13
char13 Feb. 12 at 2:07 PM
$ACOG good movements here
0 · Reply
topstockalerts
topstockalerts Feb. 12 at 2:00 PM
Pre Market Top Gainers PT2 $CGNX $COEP $ACOG $PRCH $KXIN
0 · Reply
gnarled15
gnarled15 Feb. 12 at 1:57 PM
$ACOG no volume as per usual, any buying drives this up quick
0 · Reply
theflynews
theflynews Feb. 11 at 4:46 PM
Biotech Alert: Searches spiking for these stocks today - $ACOG - https://legacy.thefly.com/permalinks/entry.php/id4290608
0 · Reply
topstockalerts
topstockalerts Feb. 10 at 6:30 PM
$ACOG Buyers stepping in with conviction. Price responds quickly to demand. That’s what strong trends look like 💪.
0 · Reply
SpyFader
SpyFader Feb. 10 at 12:57 PM
$ACOG is a women's health biotech or medical device company; requires clinical success and market adoption.
0 · Reply